Literature DB >> 23839339

Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity.

Jessica Soldavini1, Jonathan D Kaunitz.   

Abstract

BACKGROUND: The lumen of the gastrointestinal tract contains many substances produced from the breakdown of foodstuffs, from salivary, esophageal, intestinal, hepatic, and pancreatic secretions, and from sloughed cells present in the gastrointestinal lumen. Although these substances were traditionally regarded as waste products, there is increasing realization that many can be biologically active, either as signalling compounds or as nutrients. For example, proteins are broken down into amino acids, which are then sensed by nutrient receptors. The gut microbiome, which is at highest abundance in the ileocecum, has powerful metabolic activity, digesting and breaking down unabsorbed carbohydrates, proteins, and other ingested nutrients into phenols, amines, volatile organic compounds, methane, carbon dioxide, hydrogen, and hydrogen sulfide into volatile fatty acids, also called short-chain fatty acids (SCFAs).
CONCLUSION: These latter substances are the topic of this review. In this review, we will briefly discuss recent advances in the understanding SCFA production, signalling, and absorption, followed by a detailed description and discussion of trials of SCFAs, probiotics, and prebiotics in the treatment of gastrointestinal disease, in particular ulcerative colitis (UC), pouchitis, short bowel syndrome, and obesity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23839339      PMCID: PMC4317286          DOI: 10.1007/s10620-013-2744-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  114 in total

1.  Kinetics of butyrate metabolism in the normal colon and in ulcerative colitis: the effects of substrate concentration and carnitine on the β-oxidation pathway.

Authors:  V De Preter; K P Geboes; V Bulteel; G Vandermeulen; P Suenaert; P Rutgeerts; K Verbeke
Journal:  Aliment Pharmacol Ther       Date:  2011-06-26       Impact factor: 8.171

2.  Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease.

Authors:  Maria Mylonaki; Neil B Rayment; David S Rampton; Barry N Hudspith; Jonathan Brostoff
Journal:  Inflamm Bowel Dis       Date:  2005-05       Impact factor: 5.325

3.  Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils.

Authors:  Marco A R Vinolo; Hosana G Rodrigues; Elaine Hatanaka; Fábio T Sato; Sandra C Sampaio; Rui Curi
Journal:  J Nutr Biochem       Date:  2010-12-16       Impact factor: 6.048

4.  1H NMR-based metabonomic assessment of probiotic effects in a colitis mouse model.

Authors:  Young-Shick Hong; Young-Tae Ahn; Jong-Cherl Park; Jung-Hee Lee; Hoyong Lee; Chul-Sung Huh; Dong-Hyun Kim; Do Hyun Ryu; Geum-Sook Hwang
Journal:  Arch Pharm Res       Date:  2010-07-27       Impact factor: 4.946

5.  Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.

Authors:  E Furrie; S Macfarlane; A Kennedy; J H Cummings; S V Walsh; D A O'neil; G T Macfarlane
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

6.  Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoileal resection in neonatal piglets.

Authors:  Anne L Bartholome; David M Albin; David H Baker; Jens J Holst; Kelly A Tappenden
Journal:  JPEN J Parenter Enteral Nutr       Date:  2004 Jul-Aug       Impact factor: 4.016

Review 7.  Glucagon-like peptide-2 and short-chain fatty acids: a new twist to an old story.

Authors:  Kelly A Tappenden; David M Albin; Anne L Bartholome; Heather Fottler Mangian
Journal:  J Nutr       Date:  2003-11       Impact factor: 4.798

8.  Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats.

Authors:  M Song; B Xia; J Li
Journal:  Postgrad Med J       Date:  2006-02       Impact factor: 2.401

9.  Comparison of prophylactic and therapeutic use of short-chain fatty acid enemas in diversion colitis: a study in Wistar rats.

Authors:  Ariano Jose Freitas de Oliveira; Francisco Edilson Leite Pinto Júnior; Maria Célia Carvalho Formiga; Syomara Pereira da Costa Melo; Jose Brandao-Neto; Ana Maria de Oliveira Ramos
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

10.  Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms.

Authors:  Hua V Lin; Andrea Frassetto; Edward J Kowalik; Andrea R Nawrocki; Mofei M Lu; Jennifer R Kosinski; James A Hubert; Daphne Szeto; Xiaorui Yao; Gail Forrest; Donald J Marsh
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

View more
  24 in total

1.  Branched Short-Chain Fatty Acid Isovaleric Acid Causes Colonic Smooth Muscle Relaxation via cAMP/PKA Pathway.

Authors:  Bryan A Blakeney; Molly S Crowe; Sunila Mahavadi; Karnam S Murthy; John R Grider
Journal:  Dig Dis Sci       Date:  2018-12-17       Impact factor: 3.199

2.  Starch-entrapped microsphere fibers improve bowel habit but do not exhibit prebiotic capacity in those with unsatisfactory bowel habits: a phase I, randomized, double-blind, controlled human trial.

Authors:  Heather E Rasmussen; Bruce Hamaker; Kumar B Rajan; Ece Mutlu; Stefan J Green; Michael Brown; Amandeep Kaur; Ali Keshavarzian
Journal:  Nutr Res       Date:  2017-06-02       Impact factor: 3.315

3.  Neural FFA3 activation inversely regulates anion secretion evoked by nicotinic ACh receptor activation in rat proximal colon.

Authors:  Izumi Kaji; Yasutada Akiba; Kohtarou Konno; Masahiko Watanabe; Shunsuke Kimura; Toshihiko Iwanaga; Ayaka Kuri; Ken-Ichi Iwamoto; Atsukazu Kuwahara; Jonathan D Kaunitz
Journal:  J Physiol       Date:  2016-03-20       Impact factor: 5.182

Review 4.  Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?

Authors:  Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-30       Impact factor: 46.802

Review 5.  Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis.

Authors:  Susan Westfall; Nikita Lomis; Imen Kahouli; Si Yuan Dia; Surya Pratap Singh; Satya Prakash
Journal:  Cell Mol Life Sci       Date:  2017-06-22       Impact factor: 9.261

6.  Atractylone Alleviates Ethanol-Induced Gastric Ulcer in Rat with Altered Gut Microbiota and Metabolites.

Authors:  Ling Li; Yaoyao Du; Yang Wang; Ning He; Bing Wang; Tong Zhang
Journal:  J Inflamm Res       Date:  2022-08-16

7.  Chronically Elevated Levels of Short-Chain Fatty Acids Induce T Cell-Mediated Ureteritis and Hydronephrosis.

Authors:  Jeongho Park; Craig J Goergen; Harm HogenEsch; Chang H Kim
Journal:  J Immunol       Date:  2016-01-27       Impact factor: 5.422

8.  The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon.

Authors:  Norm R Hurst; Derek M Kendig; Karnam S Murthy; John R Grider
Journal:  Neurogastroenterol Motil       Date:  2014-09-16       Impact factor: 3.598

9.  Gut microbial involvement in Alzheimer's disease pathogenesis.

Authors:  Yu Zhang; Rulin Geng; Qiuyun Tu
Journal:  Aging (Albany NY)       Date:  2021-05-10       Impact factor: 5.682

Review 10.  Use of Short-Chain Fatty Acids for the Recovery of the Intestinal Epithelial Barrier Affected by Bacterial Toxins.

Authors:  Diliana Pérez-Reytor; Carlos Puebla; Eduardo Karahanian; Katherine García
Journal:  Front Physiol       Date:  2021-05-24       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.